Physician profile
Dewitt Leachman
NPI 1184647018
$11,207.94
in general payments reported to CMS, 2019-2025
43 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $635 · 2021: $1,429 · 2022: $2,188 · 2023: $1,594 · 2024: $1,788 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,490 · Debt Forgiveness: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,490.09 |
| Debt Forgiveness | $760.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,462.87 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,108.90 | 2019-2025 | Leqvio |
| Novo Nordisk INC | $835.14 | 2022-2025 | Wegovy, Ozempic, Fiasp |
| E.R. Squibb & Sons, L.L.C. | $832.34 | 2019-2025 | Eliquis, Camzyos |
| Merit Medical Systems INC | $760.84 | 2025 | |
| Amgen INC. | $657.57 | 2019-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $597.13 | 2019-2025 | Uptravi, Opsumit |
| Kowa Pharmaceuticals America, INC. | $475.42 | 2019-2023 | Livalo |
| Pfizer INC. | $438.80 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $401.53 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.28 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $320.23 | 2021-2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $268.60 | 2021-2024 | Optimizer, Optimizer |
| Amarin Pharma, INC. | $249.69 | 2022-2023 | |
| Esperion Therapeutics, INC. | $246.37 | 2020-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $197.34 | 2022-2023 | Watchman Access System, Watchman Flx |
| Irhythm Technologies, INC. | $187.69 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $151.18 | 2019 | |
| Abbott Laboratories | $144.18 | 2021-2023 | Cardiomems |
| Akcea Therapeutics, INC. | $141.47 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $134.67 | 2020-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $125.89 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $119.18 | 2019-2025 | Wainua, Farxiga |
| Astellas Pharma US INC | $115.32 | 2019-2020 | |
| Medtronic, INC. | $96.63 | 2021-2024 | Endurant Iis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.74 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $90.88 | 2022 | |
| Heartflow, INC. | $65.44 | 2022-2024 | |
| Vifor Pharma, INC. | $65.07 | 2021 | |
| Biotronik INC. | $64.70 | 2021 | |
| Baxter Healthcare | $56.52 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Endologix LLC | $47.43 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $44.31 | 2024 | Arcalyst |
| Lilly USA, LLC | $44.08 | 2025 | Zepbound, Mounjaro |
| Cardiva Medical, INC. | $42.18 | 2023 | Cardiva Vascade 6/7f Vcs |
| Avinger INC. | $35.67 | 2020-2021 | |
| Bridgebio Pharma, INC. | $33.44 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $30.86 | 2019 | |
| Chiesi USA, INC. | $28.44 | 2019 | |
| Bolton Medical INC | $25.64 | 2023 | Treo Abdominal Stent-Graft System |
| Inspire Medical Systems, INC. | $19.34 | 2024 | Inspire |
| Inari Medical, INC. | $14.64 | 2021 | |
| Cvrx, INC. | $11.30 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewitt Leachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.